Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ruth Morrell"'
Publikováno v:
Case Reports in Hematology, Vol 2013 (2013)
Mutations of MPL are present in a significant proportion of patients with the myeloproliferative neoplasms (MPN), primary myelofibrosis (PMF), and essential thrombocythaemia (ET). The most frequent of these mutations, W515L and W515K, occur in exon 1
Externí odkaz:
https://doaj.org/article/982bf98ac79e4f83ad3258fdf80df7ab
Autor:
Csaba Ortutay, Anna Halpin-McCormick, Denis V. Baev, Eva Szegezdi, Sukhraj Pal Singh Dhami, Michael O'Dwyer, John Quinn, Afshin Samali, Corrado Santocanale, Ruth Morrell, Eimear O’ Reilly
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-15 (2018)
Scientific Reports
Scientific Reports
Acute myeloid leukaemia (AML) is an aggressive cancer with 50–75% of patients relapsing even after successful chemotherapy. The role of the bone marrow microenvironment (BMM) in protecting AML cells from chemotherapeutics and causing consequent rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c979ee56475c0038232d50330eb8434
http://link.springer.com/article/10.1038/s41598-018-33982-y
http://link.springer.com/article/10.1038/s41598-018-33982-y
Autor:
Stephen E. Langabeer, Johanna Kelly, Karl Haslam, John Quinn, Eibhlin Conneally, Ruth Morrell
Publikováno v:
Clinical and Translational Oncology. 20:420-423
Chronic neutrophilic leukemia is a rare form of myeloproliferative neoplasm characterized by mature neutrophil hyperleukocytosis. The majority of patients harbor somatic mutations of CSF3R gene and are potentially amenable to targeted therapy with JA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22e8c76b167e6ccf30fcb596498ed0b1
https://doi.org/10.1007/s12094-017-1722-2
https://doi.org/10.1007/s12094-017-1722-2
Publikováno v:
Case Reports in Hematology
Case Reports in Hematology, Vol 2013 (2013)
Case Reports in Hematology, Vol 2013 (2013)
Mutations ofMPLare present in a significant proportion of patients with the myeloproliferative neoplasms (MPN), primary myelofibrosis (PMF), and essential thrombocythaemia (ET). The most frequent of these mutations, W515L and W515K, occur in exon 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e23ebadd350468ce2faec0ad2e67998
https://doi.org/10.1155/2013/729327
https://doi.org/10.1155/2013/729327
Autor:
Marianne van Dijk, Afshin Samali, Eva Szegezdi, Steven Knapper, Eoin Murphy, Michael O'Dwyer, Ruth Morrell
Publikováno v:
Cancers; Volume 3; Issue 1; Pages: 1329-1350
Cancers, Vol 3, Iss 1, Pp 1329-1350 (2011)
Cancers
Cancers, Vol 3, Iss 1, Pp 1329-1350 (2011)
Cancers
Acute myeloid leukemia (AML) is an aggressive stem cell malignancy that is difficult to treat. There are limitations to the current treatment regimes especially after disease relapse, and therefore new therapeutic agents are urgently required which c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::801026650c1adff18005c02f8c2bf1a8
https://doi.org/10.3390/cancers3011329
https://doi.org/10.3390/cancers3011329
Autor:
Ruth Morrell, Karen Cawley, Anna Halpin-McCormick, Afshin Samali, Eva Szegezdi, Michael O'Dwyer
Publikováno v:
ResearcherID
Abstract 1841 ABT-737 is a small molecule inhibitor of Bcl-2 and Bcl-xL with reported activity in pre-clinical in-vitro and in-vivo studies of acute myeloid leukaemia(AML) but to date no data has been reported on its activity in an AML co-culture mod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::821561595cdc050816f68eeb55fc67e6
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000289662202065&KeyUID=WOS:000289662202065
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000289662202065&KeyUID=WOS:000289662202065
